$26.22
0.65% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US1407553072
Symbol
TVRD
Sector
Industry

Tvardi Therapeutics Stock price

$26.22
+0.22 0.85% 1M
+16.61 172.78% 6M
+7.86 42.81% YTD
+2.36 9.87% 1Y
-512.70 95.13% 5Y
-334.14 92.72% 10Y
-438.54 94.36% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.17 0.65%
ISIN
US1407553072
Symbol
TVRD
Sector
Industry

Key metrics

Market capitalization $245.44m
Enterprise Value $211.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 27.90
P/S ratio (TTM) P/S ratio 32.42
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -55.31%
Revenue (TTM) Revenue $7.57m
EBIT (operating result TTM) EBIT $-28.14m
Free Cash Flow (TTM) Free Cash Flow $-35.61m
Cash position $34.22m
EPS (TTM) EPS $-29.56
P/E forward negative
P/S forward 377.60
EV/Sales forward 324.95
Short interest 1.70%
Show more

Is Tvardi Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Tvardi Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Tvardi Therapeutics forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Tvardi Therapeutics forecast:

Buy
100%

Financial data from Tvardi Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.57 7.57
55% 55%
100%
- Direct Costs - -
-
-
5.02 5.02
61% 61%
66%
- Selling and Administrative Expenses 24 24
12% 12%
320%
- Research and Development Expense 11 11
90% 90%
147%
-28 -28
77% 77%
-370%
- Depreciation and Amortization 0.15 0.15
53% 53%
2%
EBIT (Operating Income) EBIT -28 -28
77% 77%
-372%
Net Profit -45 -45
63% 63%
-595%

In millions USD.

Don't miss a Thing! We will send you all news about Tvardi Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tvardi Therapeutics Stock News

Neutral
GlobeNewsWire
about 2 months ago
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.
Neutral
GlobeNewsWire
about 2 months ago
STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock.
Neutral
Business Wire
4 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the comb...
More Tvardi Therapeutics News

Company Profile

Tvardi Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Head office United States
CEO Imran Alibhai
Founded 2004
Website www.caratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today